HOT2R - Heme Oxygenase-1 in renal Transplantation Research study
Research type
Research Study
Full title
Heme Oxygenase-1 in renal Transplantation Research study (HOT2R)- Research into the mechanistic action of heme arginate in renal transplant recipients (HOT2 trial participants).
IRAS ID
239808
Contact name
Katie Connor
Contact email
Sponsor organisation
University of Edinburgh
Duration of Study in the UK
2 years, 5 months, 24 days
Research summary
During transplantation, the donor kidney inevitably undergoes a period without blood supply and becomes injured (ischaemic). This ischaemic injury reduces early function of the kidney after transplant and long term is associated with increased rates of graft loss. The drug heme arginate (HA) increases the protective enzyme 'heme-oxygenase 1' (HO-1), improving ischaemic injury in studies and increasing HO-1 in kidney transplant patients (HOT1 study). In the upcoming HOT2 trial, HA will be given to kidney transplant recipients to see whether this improves function of the transplanted kidney.
We have identified that novel small RNA molecules 'microRNAs' predict the amount of HO-1 generated in individuals and therefore could be used to personalise HA treatment. We wish to investigate the role of these blood microRNAs in the upcoming HOT2 trial. We also wish to examine whether HA treatment response drives immune cells in the blood to have more protective characteristics and reduces markers of kidney transplant injury in urine.
REC name
North East - Newcastle & North Tyneside 2 Research Ethics Committee
REC reference
18/NE/0177
Date of REC Opinion
4 Jul 2018
REC opinion
Further Information Favourable Opinion